SPINOZA is a proof-of-concept expansion into Alzheimer's disease, but the primary endpoint readout is at Week 52 — no near-term binary catalyst. The BROADWAY biomarker signal provides scientific rationale but does not guarantee Phase 2b success. Monitor enrollment updates and any interim biomarker data.
Price Chart
Executive Summary
NewAmsterdam Pharma announced the dosing of the first patient in SPINOZA, a Phase 2b trial evaluating obicetrapib in ~400 participants with preclinical Alzheimer's disease. The trial is informed by a prespecified biomarker analysis from the Phase 3 BROADWAY trial that showed statistically significant p-tau217 reductions. This is an early-stage pipeline expansion with no financial data or near-term catalyst — the primary endpoint readout is at Week 52, likely 12+ months away.
Key Facts
- First patient dosed in Phase 2b SPINOZA trial (obicetrapib) for preclinical Alzheimer's disease
- Trial targets ~400 participants with ApoE4/E4, ApoE3/E4, or ApoE3/E3 genotypes
- Primary endpoint: change in plasma p-tau217 from baseline to Week 52
- BROADWAY biomarker analysis showed statistically significant p-tau217 reduction vs placebo (p=0.025 full set; p=0.022 ApoE4 carriers)
- 52-week double-blind period followed by 26-week open-label extension
Financial Impact
No financial figures disclosed; trial costs not quantified
Risk Factors
- Phase 2b may fail to replicate BROADWAY biomarker signals in a preclinical population
- Alzheimer's disease drug development has high failure rates
- No financial data or guidance provided in this filing
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-406063 |
| Document: nams-ex99_1.htm | 0001193125-26-406063 |
| Document: 0001193125-26-406063-index-headers.html | 0001193125-26-406063 |
| Document: 0001193125-26-406063-index.html | 0001193125-26-406063 |
| Document: 0001193125-26-406063.txt | 0001193125-26-406063 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 29, 2026 27d ago | 8-K | $23.81 $24.32 | ▲ +2.14% | ▲ +2.35% | $19.53 (−17.98%) |
Sep 22, 2026 4w ago | SC 13D/A | $22.68 $22.74 | ▲ +0.26% | ▲ +0.35% | $19.53 (−13.89%) |
Sep 15, 2026 5w ago | Insider Buy | $21.18 $21.93 | ▲ +3.54% | ▲ +2.41% | $19.53 (−7.79%) |
Aug 5, 2026 11w ago | 8-K | $27.42 $27.67 | ▲ +0.91% | ▲ +1.07% | $19.53 (−28.77%) |
Jul 24, 2026 13w ago | 8-K | $29.64 $30.22 | ▲ +1.96% | ▲ +1.94% | $19.53 (−34.11%) |
Apr 8, 2026 28w ago | Press Release | $34.01 $35.07 | ▲ +3.12% | ▲ +2.54% | $19.53 (−42.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers